AstraZeneca PLC
1583.50
14-February-25 11:29:52
15 minutes delayed
Stocks
-37.50
-2.31%
Today's range
1580.50 - 1612.00
ISIN
N/A
Source
NASD.OMX SE
-
AstraZeneca's Imfinzi Gets US Approval For Resectable Early-stage Lung Cancer
16 Aug 2024 03:28:46 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
16 Aug 2024 03:17:04 By NetDania Notify
-
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
15 Aug 2024 07:38:12 By NASDAQ Stocks
-
NetDania - New 12 months High: AstraZeneca PLC
15 Aug 2024 03:15:16 By NetDania Notify
-
NetDania - New 12 months High: AstraZeneca PLC
13 Aug 2024 03:19:30 By NetDania Notify
-
Ex-Dividend Reminder: Cencora, AstraZeneca and Wells Fargo
07 Aug 2024 10:27:01 By NASDAQ Stocks
-
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
04 Aug 2024 10:42:17 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
29 Jul 2024 08:07:19 By NetDania Notify
-
AstraZeneca: Calquence Combo Enhances PFS In First-Line CLL In Phase III Trial
29 Jul 2024 03:38:02 By NASDAQ US Markets
-
AstraZeneca Reports ODAC's Review Of Imfinzi - Quick Facts
26 Jul 2024 03:05:05 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
25 Jul 2024 03:15:03 By NetDania Notify
-
AstraZeneca Q2 Profit Rises, Lifts FY24 Outlook
25 Jul 2024 02:51:34 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
23 Jul 2024 06:15:26 By NetDania Notify
-
NetDania - New 12 months High: AstraZeneca PLC
22 Jul 2024 08:17:57 By NetDania Notify
-
Interesting AZN Put And Call Options For August 23rd
03 Jul 2024 13:16:51 By NASDAQ US Markets
-
AstraZeneca: CHMP Recommends Lynparza And Imfinzi Combination For EU Approval In Endometrial Cancer
01 Jul 2024 03:09:21 By NASDAQ US Markets
-
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
28 Jun 2024 10:33:02 By NASDAQ Stocks
-
AstraZeneca: Imfinzi Trial Fails To Meet Endpoint In Early-stage Non-small Cell Lung Cancer
25 Jun 2024 03:08:02 By NASDAQ US Markets
-
AstraZeneca: Phase III Truqap Trial Plus Chemotherapy Fails To Meet Primary Goals In Breast Cancer
18 Jun 2024 03:15:21 By NASDAQ US Markets
-
AstraZeneca's Calquence Combo Cuts Progression Risk By 27% In Mantle Cell Lymphoma Trial
16 Jun 2024 12:33:03 By NASDAQ US Markets